%0 Journal Article %T Additional Treatment Modality to Improve Outcomes in Myocardial Infarctions and Strokes %A Simon Skurkovich %A Boris Skurkovich %J Journal of Immune Based Therapies, Vaccines and Antimicrobials %P 29-31 %@ 2168-1554 %D 2014 %I Scientific Research Publishing %R 10.4236/jibtva.2014.32004 %X
In 1974, in Nature, we hypothesized that removal of cytokines can be effective in the treatment of certain inflammatory diseases, e.g., rheumatoid arthritis (RA). We call this approach anticytokino-therapy. Later it was shown that neutralization of pro-inflammatory cytokines, such as tumor necrosis factor alpha (TNF-¦Á), interferon alpha (IFN-¦Á), interferon gamma (IFN-¦Ã), and interleukin 6 (IL-6), leads to a good therapeutic effect. Anticytokinotherapy is currently used around the world for the treatment of rheumatoid arthritis, psoriasis, psoriatic arthritis, and other Th-1-mediated inflammatory diseases. Pro-inflammatory cytokines have also been found in other conditions (myocardial infarctions, strokes, chronic pain syndromes, etc.). This leads us to believe that hyper- production of pro-inflammatory cytokines forms a basis of a variety of pathological conditions and represents a uniform response of the organism to a wide variety of insults in any part of the body. Thus, we propose to add monoclonal antibodies to (or other blockers of) pro-inflammatory cytokines to the treatment regimens for myocardial infarctions, strokes, and possibly other Th-1-mediated diseases.
%K Neutralization of Pro-Inflammatory Cytokines %K Myocardial Infarction %K Stroke %U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=44945